EveryONE Medicines

Kent Rogers, CEO of EveryONE Medicines, spoke today at the Advancing Rare Disease Therapies Through an FDA Rare Disease HUB in Silver Spring, MD. #nof1 #raredisease #ultrararedisease

EveryONE Medicines will be attending the World Orphan Drug Congress Europe 2024 in Barcelona, Oct 22 - 25. We will be in the Start-Up Zone, Pod S1, Kent Rogers, Deb Gouveia, Srinivas Chunduru, and Andrew Roddam. You can use the below link to register and receive a discount. https://lnkd.in/e2GHzZ79 #nof1 #raredisease #ultrararedisease

Yesterday, Kent Rogers, CEO at EveryONE Medicines, participated in a panel discussion "What Are You Innovating" at the Precision Medicine Summit 2024, in Austin, TX, to support the To Cure A Rose Foundation. #nof1 #raredisease #Ultrararedisease

EveryONE Medicines attends the Rose Fest at the Haute Spot, Austin, TX to support the To Cure A Rose Foundation. Julia Vitarello Deb Gouveia Irina Antonijevic MD PhD Kent Rogers To Cure A Rose Foundation #nof1 #raredisease #ultrararedisease

STAT speaks with our co-founder Julia Vitarello about bespoke #genetic therapies. “Vitarello was unexpectedly plunged into the rare-disease world when her daughter, Mila, was diagnosed with Batten disease and in 2018 became the first person to receive a tailored genetic therapy. Mila passed away in 2021 after showing initial improvements, but Vitarello has continued to grapple with the structural barriers that have led only about a dozen other patients to receive personalized ASOs — often only after herculean efforts by doctors and parents. She’s part of a consortium that is brainstorming ways to carve out a smoother path for bespoke medicines in the U.K., and Vitarello co-founded EveryONE Medicines, a company working to show that there’s a viable business model in developing personalized therapies. She points out that the traditional model of submitting individual drug applications for each new therapy and insurers expecting regulatory approval isn’t feasible for therapies for especially rare diseases. Instead, she’d like to see regulators shift toward approving the processes used by makers of customized therapies as long as they meet certain basic standards and have a successful track record.” Read the article by Jonathan Wosen, PhD: https://lnkd.in/eH-NhvBT

Thanks BioSpace for speaking with our CEO Kent Rogers, co-founder Julia Vitarello and investor Nessan Bermingham from Khosla Ventures. With genome sequencing becoming cheaper and more accessible, the door to personalized genetic medicines for devastating diseases is cracking open and companies like EveryONE Medicines and Cure Rare Disease are determined to walk through, making such therapies commercially viable in the process. “This is a new sort of paradigm, the individualized medicine paradigm,” said Julia Vitarello, co-founder of EveryONE. Read the article by senior editor Heather McKenzie: https://lnkd.in/e_kg3dmd

Fifty-five years ago, today - July 20, 1969, Apollo 11 landed on the Moon. This was such a farfetched concept and hard to comprehend. Why would we want to do this? "We choose to go to the moon in this decade and do the other things, not because they are easy, but because they are hard, because that goal will serve to organize and measure the best of our energies and skills, because that challenge is one that we are willing to accept, one we are unwilling to postpone, and one which we intend to win, and the others, too," said former President John F. Kennedy. That statement resonates with us at EveryONE Medicines. We are challenging ourselves by developing personalized genetic medicines for patients with unique mutations. We are at the forefront of this effort and vow to help the Mila's of the world. Our hope is that soon, this will be the norm as Julia Vitarello continues to champion for this treatment paradigm. #nof1 #raredisease #ultrararedisease

EveryONE Medicines Appoints New CEO And Chairman Learn more & get our take 👇 https://lnkd.in/gyMN-PkN “We are thrilled to welcome Kent Rogers as CEO of EveryONE Medicines. With over 30 years of experience in product commercialization, supply chain logistics and market access strategy, Kent brings a wealth of knowledge and expertise to the team.” — Dr. Nessan Bermingham, Partner at Khosla Ventures “Our business model is unique to the industry, leveraging state-of-the-art genome sequencing, AI-driven innovation and advanced manufacturing capabilities.” — Kent Rogers, CEO at EveryONE Medicines “Technology is no longer the limiting factor. We can now find the underlying genetic cause of disease in children like Mila and develop a medicine that targets it, even if unique to one or just a few patients.” — Julia Vitarello, Co-founder at EveryONE Medicines #leadership #medicine #SoHCNews

Welcome Kent Rogers! It is great to have you on the team.

We’re excited to announce the appointment of Kent Rogers as Chief Executive Officer and Joshua Ofman MD, MSHS as Chairman of the Board. 🧬🧬 EveryONE Medicines is the first biotech company solely dedicated to developing personalized genetic medicines, and was founded with seed financing from Khosla Ventures, GV (Google Ventures), Third Rock Ventures and a private healthcare investment fund, to develop a scalable pathway for treatments tailored to individual patients with unique genetic mutations. Inspired by the story of Mila, EveryONE Medicines was founded on the commitment to make individualized medicines commercially viable and in turn accessible to anyone who can benefit from them. Read the press release: https://lnkd.in/d5Dp4qPn Learn more about Mila's story: https://lnkd.in/dxaQz5sa